ZA9811592B - Molecular dispersion composition with enhanced bioavailability - Google Patents
Molecular dispersion composition with enhanced bioavailabilityInfo
- Publication number
- ZA9811592B ZA9811592B ZA9811592A ZA9811592A ZA9811592B ZA 9811592 B ZA9811592 B ZA 9811592B ZA 9811592 A ZA9811592 A ZA 9811592A ZA 9811592 A ZA9811592 A ZA 9811592A ZA 9811592 B ZA9811592 B ZA 9811592B
- Authority
- ZA
- South Africa
- Prior art keywords
- dispersion composition
- molecular dispersion
- enhanced bioavailability
- bioavailability
- enhanced
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
- A61K9/146—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic macromolecular compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4841—Filling excipients; Inactive ingredients
- A61K9/4866—Organic macromolecular compounds
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US99716897A | 1997-12-22 | 1997-12-22 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ZA9811592B true ZA9811592B (en) | 1999-06-17 |
Family
ID=25543717
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ZA9811592A ZA9811592B (en) | 1997-12-22 | 1998-12-17 | Molecular dispersion composition with enhanced bioavailability |
Country Status (28)
| Country | Link |
|---|---|
| EP (1) | EP1039908B1 (cs) |
| JP (2) | JP2001526227A (cs) |
| KR (1) | KR100597331B1 (cs) |
| CN (1) | CN1116039C (cs) |
| AR (1) | AR017436A1 (cs) |
| AT (1) | ATE260105T1 (cs) |
| AU (1) | AU761994C (cs) |
| BR (1) | BR9813728A (cs) |
| CA (1) | CA2315685C (cs) |
| CO (1) | CO4970793A1 (cs) |
| CZ (1) | CZ295956B6 (cs) |
| DE (1) | DE69821984T2 (cs) |
| DK (1) | DK1039908T3 (cs) |
| ES (1) | ES2214757T3 (cs) |
| HK (1) | HK1027040A1 (cs) |
| HU (1) | HU229052B1 (cs) |
| ID (1) | ID28304A (cs) |
| IL (1) | IL136460A0 (cs) |
| MY (1) | MY126580A (cs) |
| NO (1) | NO327383B1 (cs) |
| NZ (1) | NZ504834A (cs) |
| PE (1) | PE20000012A1 (cs) |
| PL (1) | PL192423B1 (cs) |
| PT (1) | PT1039908E (cs) |
| SK (1) | SK285662B6 (cs) |
| TW (1) | TW527196B (cs) |
| WO (1) | WO1999032118A1 (cs) |
| ZA (1) | ZA9811592B (cs) |
Families Citing this family (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6524832B1 (en) | 1994-02-04 | 2003-02-25 | Arch Development Corporation | DNA damaging agents in combination with tyrosine kinase inhibitors |
| US6632455B2 (en) | 1997-12-22 | 2003-10-14 | Schering Corporation | Molecular dispersion composition with enhanced bioavailability |
| US6316462B1 (en) | 1999-04-09 | 2001-11-13 | Schering Corporation | Methods of inducing cancer cell death and tumor regression |
| ES2333645T3 (es) | 2001-06-22 | 2010-02-25 | Bend Research, Inc. | Composiciones farmaceuticas de dispersiones de medicamentos y polimeros neutros. |
| EP1492508A4 (en) * | 2002-03-04 | 2009-05-06 | Teva Pharma | DOSAGE FORMS WITH CONTROLLED RELEASE |
| SA07280459B1 (ar) | 2006-08-25 | 2011-07-20 | بيورديو فارما إل. بي. | أشكال جرعة صيدلانية للتناول عن طريق الفم مقاومة للعبث تشتمل على مسكن شبه أفيوني |
| PT103661B (pt) | 2007-02-23 | 2010-09-07 | Hovione Farmaciencia S A | Processo de preparação de minociclina base cristalina |
| WO2008136394A1 (ja) * | 2007-04-27 | 2008-11-13 | Ajinomoto Co., Inc. | ラクタム化合物の製造方法及びその製造中間体 |
| US8835635B2 (en) * | 2012-06-05 | 2014-09-16 | Symed Labs Limited | Amorphous form of vilazodone hydrochloride substantially free of crystalline forms |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE2546577B2 (de) * | 1975-10-17 | 1981-04-02 | Sandoz-Patent-GmbH, 7850 Lörrach | Feste Stoffe aus Polyvinylpyrrolidon und Ergotalkaloiden |
| EP0214092A1 (en) * | 1985-08-08 | 1987-03-11 | Ciba-Geigy Ag | Enhanced absorption of psychoactive 2-aryl-pyrazolo quinolines as a solid molecular dispersion in polyvinylpyrrolidone |
| JP3722293B2 (ja) * | 1991-12-18 | 2005-11-30 | ワーナー−ランバート・カンパニー、リミテッド、ライアビリティ、カンパニー | 新規な薬学的固体分散物 |
| JPH0848632A (ja) * | 1994-08-08 | 1996-02-20 | Kanebo Ltd | エトポシドを含有する固形組成物および固形製剤 |
| NZ326035A (en) * | 1995-12-22 | 2000-01-28 | Schering Corp | Tricyclic amides useful for inhibition of g-protein function and for treatment of proliferative diseases |
| WO1998000113A1 (en) * | 1996-06-28 | 1998-01-08 | Schering Corporation | Solid solution of an antifungal agent with enhanced bioavailability |
-
1998
- 1998-12-17 WO PCT/US1998/026218 patent/WO1999032118A1/en active IP Right Grant
- 1998-12-17 PE PE1998001243A patent/PE20000012A1/es not_active Application Discontinuation
- 1998-12-17 AU AU18143/99A patent/AU761994C/en not_active Expired
- 1998-12-17 HU HU0100850A patent/HU229052B1/hu not_active IP Right Cessation
- 1998-12-17 PL PL341344A patent/PL192423B1/pl not_active IP Right Cessation
- 1998-12-17 KR KR1020007006866A patent/KR100597331B1/ko not_active IP Right Cessation
- 1998-12-17 CA CA002315685A patent/CA2315685C/en not_active Expired - Lifetime
- 1998-12-17 NZ NZ504834A patent/NZ504834A/en not_active IP Right Cessation
- 1998-12-17 EP EP98963031A patent/EP1039908B1/en not_active Expired - Lifetime
- 1998-12-17 CO CO98075234A patent/CO4970793A1/es unknown
- 1998-12-17 JP JP2000525109A patent/JP2001526227A/ja not_active Withdrawn
- 1998-12-17 CN CN98812483A patent/CN1116039C/zh not_active Expired - Fee Related
- 1998-12-17 AR ARP980106455A patent/AR017436A1/es active IP Right Grant
- 1998-12-17 ID IDW20001216A patent/ID28304A/id unknown
- 1998-12-17 TW TW087121048A patent/TW527196B/zh not_active IP Right Cessation
- 1998-12-17 IL IL13646098A patent/IL136460A0/xx not_active IP Right Cessation
- 1998-12-17 BR BR9813728-0A patent/BR9813728A/pt not_active Application Discontinuation
- 1998-12-17 CZ CZ20002304A patent/CZ295956B6/cs not_active IP Right Cessation
- 1998-12-17 MY MYPI98005697A patent/MY126580A/en unknown
- 1998-12-17 ZA ZA9811592A patent/ZA9811592B/xx unknown
- 1998-12-17 DK DK98963031T patent/DK1039908T3/da active
- 1998-12-17 SK SK896-2000A patent/SK285662B6/sk not_active IP Right Cessation
- 1998-12-17 ES ES98963031T patent/ES2214757T3/es not_active Expired - Lifetime
- 1998-12-17 DE DE69821984T patent/DE69821984T2/de not_active Expired - Lifetime
- 1998-12-17 PT PT98963031T patent/PT1039908E/pt unknown
- 1998-12-17 AT AT98963031T patent/ATE260105T1/de active
-
2000
- 2000-06-21 NO NO20003235A patent/NO327383B1/no not_active IP Right Cessation
- 2000-10-09 HK HK00106351A patent/HK1027040A1/xx not_active IP Right Cessation
-
2009
- 2009-12-16 JP JP2009285733A patent/JP2010059212A/ja not_active Withdrawn
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| HUP0101532A3 (en) | Improved interferon polymer conjugates | |
| HUP0000660A2 (en) | Epoxy-polysiloxane polymer composition | |
| IL124819A0 (en) | Polymer compositions | |
| ZA983899B (en) | Polymer compositions | |
| HUP0100850A3 (en) | Molecular dispersion composition with enhanced bioavailability | |
| GB9805693D0 (en) | Polymeric composition | |
| GB9800685D0 (en) | Polymer composition | |
| SG77209A1 (en) | Polymer | |
| GB2329182B (en) | Polymer blend | |
| GB9716454D0 (en) | Polymer | |
| ZA9810472B (en) | An antimalarial composition | |
| GB2325893B (en) | Folders | |
| ZA974338B (en) | Anitfungal compositions with improved bioavailability | |
| GB9716375D0 (en) | Polymer composition | |
| HU1281U (en) | Multi purpose shoe-last | |
| AUPO482297A0 (en) | Extending property post | |
| GB9727134D0 (en) | Polymers | |
| GB9718909D0 (en) | Polymers | |
| ZA983923B (en) | Biofuncational polymers | |
| GB9718133D0 (en) | Polymers | |
| GB9700114D0 (en) | Pseudo-catenane polymers | |
| GB9700897D0 (en) | Ethynylbenzine polymers | |
| GB9701813D0 (en) | Polymers | |
| GB9712744D0 (en) | Polymers | |
| HUP0000866A3 (en) | Polymers |